...
By Sam Stevenson
Associate News Editor
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
Wegovy, the weight loss drug used by millions of Americans, is now available in pill form – removing the need for invasive shots and improving access to the life-changing treatment.
Why It Matters
The launch of the daily Wegovy pill represents a significant development in obesity treatment in the United States. Obesity affects more than 100 million Americans and has been linked to increased risks for heart disease, stroke, and type 2 diabetes. The pill, the first and only FDA-approved oral GLP-1 receptor agonist for weight loss, broadens access for Americans who previously faced affordability and access barriers with weekly injectable formulations.
Read More on News
...
What To Know
The daily oral Wegovy pill, manufactured by Novo Nordisk, became available in U.S. pharmacies on Monday, following Food and Drug Administration (FDA) approval in December 2025.
The new oral pill is seen as a potential game-changer, reducing costs and logistical challenges for patients struggling to lose weight and manage obesity-related health risks.
It contains semaglutide, the same active ingredient as the injectable version of Wegovy.
The lowest 1.5 mg starter dose is priced at $149 per month for patients paying directly, with higher doses expected to be available by the end of the launch week.
The 4 mg pill remains at $149 per month until April 15, after which the price rises to $199.
Meanwhile, the higher-strength 9 mg and 25 mg doses cost $299 per month.
Patients with insurance may pay as little as $25 per month, according to Novo Nordisk’s savings program.
Novo Nordisk says the efficacy of the Wegovy pill is supported by results from the phase 3 OASIS 4 trial, which found an average weight loss of 14 percent over 64 weeks among patients taking the pill versus 2 percent for those taking a placebo, when combined with a reduced-calorie diet and exercise.
In the trial, up to 17 percent weight loss was observed in patients who remained on the treatment.
The oral pill requires patients to take the medication on an empty stomach with a small amount of water and wait at least 30 minutes before eating, drinking, or taking other medications.
Common side effects are similar to those of injectable semaglutide, including nausea, diarrhea, and vomiting.
In clinical studies, 7 percent of participants taking the Wegovy pill discontinued treatment because of side effects, compared to 6 percent for the placebo group.
It is not recommended for individuals under 18 and should not be used by people with a personal or family history of certain thyroid cancers or other specified conditions.
Rival pharmaceutical company Eli Lilly is developing its own oral GLP-1 medication, orforglipron, which is also expected to be priced from $149/month and may be approved by the FDA later in 2026.
What People Are Saying
Dave Moore, executive director of U.S. operations at Novo Nordisk, in an interview broadcast on Good Morning America on January 5: “We are launching the Wegovy pill like we have never launched before. It's our opportunity to bring this new medicine to market in all channels, all at once. Having it available through commercial insurance from day one, and available in brick-and-mortar pharmacies like CVS and Costco, but then also partnering with telehealth companies.”
Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk, said: “We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy in a once-daily pill.” He called the launch “a significant innovation as the first and only GLP-1 pill for weight loss.”
What Happens Next
The introduction of the Wegovy pill is expected to increase demand for prescription weight loss treatments as more patients gain access. Novo Nordisk's launch strategy—involving brick-and-mortar pharmacies, telehealth partnerships, and expanded savings programs—aims to reach patients who previously could not afford or access injectables.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines